Head-to-head · WeighScore
Maves vs TeleHealth Med
The verdict
Maves takes it — 71.8/100 to 66.1/100.
Maves grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Maves, operating under parent company Homera Health, is a performance-framed telehealth platform offering compounded semaglutide and tirzepatide for weight loss plus sermorelin for anti-aging, with…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Maves | TeleHealth Med |
|---|---|---|
| WeighScore | 71.8/100 | 66.1/100 |
| Grade | C | C |
| Scorecard rank | #89 | #209 |
| Semaglutide | $99/mo (starting dose, first-month rate, compounded) | $147/mo (starting dose, compounded) |
| Tirzepatide | Not disclosed | Not disclosed |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Yes |
Graded #89 · C
Strengths
- LegitScript Certified
- Publishes the FDA compounded-medication disclaimer
- $99/mo first-month intro pricing on semaglutide — among the most aggressive we track
- All 50 states covered, stated explicitly
- Both brand (Maves) and parent (Homera Health) disclosed for accountability
Where it loses points
- 503A pharmacy partner not named (only 'licensed U.S. pharmacies')
- Tirzepatide pricing not stated on the homepage — only listed as an offering
- Named medical director / clinical leadership not disclosed
- Refund and cancellation policy not detailed publicly
- Corporate address and arbitration venue not disclosed
Graded #209 · C
Strengths
- Corporate entity disclosed (TeleHealth Med, Inc.) — clearer accountability than undisclosed competitors
- Publishes the FDA compounded-medication disclaimer
- 503A pharmacy designation stated in the FAQ
- Honest disclosure that testimonials are compensated and results aren't independently verified
- Both injectable and sublingual forms offered
Where it loses points
- Specific 503A pharmacy partner not named
- LegitScript ID number not shown in text — only a verification link
- Full states-served list not disclosed
- Named medical director not disclosed
- Dose tiers beyond the $147/mo starting price not published
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.